five

Phase 3, Prospective, Randomized, Multi-center Clinical Study Comparing the Safety and Efficacy of BAX 855 Following PK-guided Prophylaxis Targeting Two Different FVIII Trough Levels in Subjects With Severe Hemophilia A

收藏
DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接:
https://search.vivli.org/doiLanding/studies/00006555/isLanding
下载链接
链接失效反馈
官方服务:
资源简介:
1. To compare the efficacy and safety of pharmacokinetic (PK)-guided treatment with BAX 855 targeting FVIII trough levels of 1-3% and approximately 10% (8-12%) 2. To further characterize pharmacokinetic (PK) and pharmacodynamic (PD) parameters of BAX 855
提供机构:
Vivli
创建时间:
2021-01-19
二维码
社区交流群
二维码
科研交流群
商业服务